Skip to Main Content


Gastrointestinal (GI) decontamination is a controversial issue in medical toxicology. It plays a central role in the initial management of orally poisoned patients and frequently is the only treatment available other than routine supportive care. Unfortunately, as is true in most areas of medical toxicology, valid studies that demonstrate the effects of GI decontamination on clinically meaningful endpoints are difficult to find. The heterogeneity of poisoned patients demands that very large randomized studies be performed because most patients who present to an emergency department (ED) have an unreliable history and a low-risk exposure. These factors, as well as other significant sources of bias, are often hidden in inclusion and exclusion criteria of the available studies. The numerous consequential determinants contribute to the difficulties in designing and completing studies that provide sound evidence for or against a particular therapeutic option. Incontrovertible endpoints, such as complication-specific mortality, also demand exceptionally large studies because the overall morbidity and mortality of poisoned patients is quite low. Whereas other endpoints, such as the length of stay in the hospital or intensive care unit (ICU), change in xenobiotic concentration, the rate of secondary complications, and the need for specific treatments such as expensive antidotes, must be considered, these surrogate markers are not adequately rigorous and are inadequately precise measures of morbidity. In the science of GI decontamination, we are also faced with the dilemma that randomizing half of a group of potentially ill patients to no decontamination is a significant ethical concern—we rarely omit decontamination unless a minimally toxic exposure has occurred or an effective, safe, readily available, and inexpensive antidote exists. Because acetaminophen meets many of these parameters, it has been used both as the xenobiotic of choice in volunteer overdose studies28,59,67,159 and in a recent Australian evaluation of actually poisoned patients.37 However, despite its widespread use as a model, the applicability of the management approach for acetaminophen poisoning to other ingestions is limited.


As might be suspected, no available study provides adequate guidance for the management of a patient who has definitely ingested an unknown xenobiotic at an unknown time. Fortunately, in most cases, there is some component of the history or clinical presentation, such as vital signs, physical examination, and focused diagnostic studies such as an ECG and anion gap, that might offer insight into the nature of the ingested xenobiotic (Chap. 3).


For many, the ongoing controversy or debate on GI decontamination culminated in 1997 with the publication of the position statements on activated charcoal, orogastric lavage, syrup of ipecac induced emesis, and whole-bowel irrigation (WBI) from the American Academy of Clinical Toxicology (AACT) and the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT).29,86,124,125,142,151, 152, 153 Contrary to initial expectations, these excellent reviews failed to end the debate; they simply highlighted many shortcomings and ambiguities within this field. A 2000 study concluded that despite having the evidence ...

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.


About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Subscription Options

AccessPharmacy Full Site: One-Year Subscription

Connect to the full suite of AccessPharmacy content and resources including 30+ textbooks such as Pharmacotherapy: A Pathophysiologic Approach and Goodman & Gilman's The Pharmacological Basis of Therapeutics, high-quality videos, images, and animations, interactive board review, drug and herb/supplements databases, and more.

$595 USD
Buy Now

Pay Per View: Timed Access to all of AccessPharmacy

24 Hour Subscription $34.95

Buy Now

48 Hour Subscription $54.95

Buy Now

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.